Healthcare Costs Associated with Complications in Patients with Type 2 Diabetes among 1.85 Million Adults in Beijing, China

• Published in: International journal of environmental research and public health Vol. 18; no. 7; p. 3693
• Main Authors: Wu, Jun-Hui, Wu, Yao, Wang, Zi-Jing, Wu, Yi-Qun, Wu, Tao, Wang, Meng-Ying, Wang, Xiao-Wen, Wang, Si-Yue, Wang, Jia-Ting, Yu, Huan, Hu, Yong-Hua
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2021; MDPI
• Subjects: Age; Cardiovascular disease; Cerebrovascular disease; Coma; Consumer Price Index; Costs; Demographics; Developing countries; Diabetes; Health services utilization; Hospitals; Kidney diseases; LDCs; Normal distribution; Patients; Statistical analysis; Beijing China; China; complication; healthcare utilization; cost analysis; diabetes
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph18073693

We aimed to provide reliable regression estimates of expenditures associated with various complications in type 2 diabetics in China. In total, 1,859,039 type 2 diabetes patients with complications were obtained from the Beijing Medical Claim Data for Employees database from 2008 to 2016. We estimated costs for complications using a generalized estimating equation model adjusted for age, sex, and the incidence of various complications. The average total cost for diabetic patients with complications was 17.12 thousand RMB. Prescribed drugs accounted for 63.4% of costs. We observed a significant increase in costs in the first year after the onset of complications. Compared with costs before the incidence of complications, the additional costs per person in the first year and >1 year after the event would be 10,631.16 RMB and 1150.71 RMB for cardiovascular disease, 1017.62 RMB and 653.82 RMB for cerebrovascular disease, and 301.14 RMB and 624.00 RMB for kidney disease, respectively. The estimated coefficients for outpatient visits were relatively lower than those of inpatient visits. Complications in diabetics exert a significant impact on total healthcare costs in the first year of their onset and in subsequent years. Our estimates may assist policymakers in quantifying the economic burden of diabetes complications.